{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=18", "query": { "intervention": "One cycle", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 2770, "total_pages": 277, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T03:25:56.414Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06414356", "title": "The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neuropathic Pain", "PTSD" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Magnesium sulfate", "type": "DRUG" }, { "name": "Ketamine + Magnesium sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Margaux M. Salas, PhD", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2024-10-02", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414356" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT00840853", "title": "Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia (ALL)", "Chronic Lymphocytic Leukemia (CLL)", "Non Hodgkin's Lymphoma" ], "interventions": [ { "name": "CD19CAR/virus specific T cells", "type": "GENETIC" }, { "name": "Benadryl and Tylenol", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 68, "start_date": "2009-04", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840853" }, { "nct_id": "NCT03901339", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 543, "start_date": "2019-05-08", "completion_date": "2023-10-20", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 55, "location_summary": "Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03901339" }, { "nct_id": "NCT01951105", "title": "Effect of L-dopa In Subacute Back Pain Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sub-acute Back Pain" ], "interventions": [ { "name": "Naproxen", "type": "DRUG" }, { "name": "Carbidopa/Levodopa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2015-02-24", "completion_date": "2017-09-25", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951105" }, { "nct_id": "NCT00797966", "title": "Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "OPC-34712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 850, "start_date": "2009-05", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2016-02-29", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 50, "location_summary": "Arcadia, California • Beverly Hills, California • Escondido, California + 43 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00797966" }, { "nct_id": "NCT00567177", "title": "Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Treatment of Dry Eye Disease" ], "interventions": [ { "name": "Restasis, Refresh Plus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovative Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 40, "start_date": "2007-11", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2010-07-30", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "6400 Fannin Ste 1800, Texas", "locations": [ { "city": "6400 Fannin Ste 1800", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567177" }, { "nct_id": "NCT02155257", "title": "Pain Expectations in Subjects With Osteoarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2014-07", "completion_date": "2017-10", "has_results": true, "last_update_posted_date": "2019-03-07", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02155257" }, { "nct_id": "NCT04520139", "title": "Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Cognitive Impairment" ], "interventions": [ { "name": "N-Acetyl-Cysteine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 102, "start_date": "2026-05-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04520139" }, { "nct_id": "NCT05013437", "title": "Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Evomela", "type": "DRUG" }, { "name": "Next Generation Sequencing", "type": "DEVICE" }, { "name": "Prochlorperazine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Koen van Besien", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-09", "completion_date": "2024-03", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-25T03:25:56.414Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013437" } ] }